Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil
- PMID: 18463934
- DOI: 10.1007/s10067-008-0908-y
Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil
Abstract
We determined, in our surrounding environment, the proportion of patients being treated with infliximab who required a therapeutic scheme escalation (an infliximab dose increase surpassing the level of 3 mg/kg every 8 weeks and/or a decrease on the current between infusions' interval). This was a study of the retrospective analysis of data from the 41 rheumatoid arthritis (RA) patients receiving an infliximab therapy at the Albert Einstein Israelita Hospital, from January 2001 up to December 2005. A questionnaire was applied to these patients, assessing their clinical and laboratory data, adverse events, and individual information regarding the infliximab administration. Therapeutic dose information was available in 68% (28/41) of the RA patients, with 46% of these (13/28) receiving a dose increase, and 30% (8/27) experiencing a shortening of the between infusions' interval. The average final infliximab dose (4.21 mg/kg) was significantly greater than their average initial dose (3.29 mg/kg). The average time intervals between the initial and final infusions, though shortened, were not significantly different. A proportion of 73% (30/41) of these patients demonstrated improvement in at least one of the assessed clinical parameters, and 50% of these patients (15/30) experienced a dose increase, while 20% (6/30) experienced shortening of the between treatments' interval. A total of 20% (8/41) of the original patients experienced adverse events. Although infliximab is effective in the control of RA, dose adjustment and/or shortening of the between treatments' interval is frequently required.
Similar articles
-
Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74. Clin Exp Rheumatol. 2005. PMID: 16095114 Clinical Trial.
-
Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1. J Med Econ. 2012. PMID: 22332705
-
National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.J Med Econ. 2014 Jan;17(1):1-10. doi: 10.3111/13696998.2013.856314. Epub 2013 Oct 31. J Med Econ. 2014. PMID: 24131136
-
Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.BioDrugs. 2002;16(2):111-48. doi: 10.2165/00063030-200216020-00005. BioDrugs. 2002. PMID: 11985485 Review.
-
Dose optimization of infliximab in patients with rheumatoid arthritis.Int J Rheum Dis. 2014 Jan;17(1):5-18. doi: 10.1111/1756-185X.12202. Epub 2013 Nov 1. Int J Rheum Dis. 2014. PMID: 24472261 Review.
Cited by
-
Anti-interleukin 6: first line in rheumatoid arthritis?Clin Rheumatol. 2009 Aug;28(8):877-9. doi: 10.1007/s10067-009-1182-3. Epub 2009 May 5. Clin Rheumatol. 2009. PMID: 19415377 No abstract available.
-
Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.Drug Saf. 2019 Sep;42(9):1091-1102. doi: 10.1007/s40264-019-00844-z. Drug Saf. 2019. PMID: 31168709
-
Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients.Clin Rheumatol. 2016 Jul;35(7):1719-23. doi: 10.1007/s10067-016-3268-z. Epub 2016 Apr 23. Clin Rheumatol. 2016. PMID: 27106543
-
Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital.Einstein (Sao Paulo). 2013 Dec;11(4):492-4. doi: 10.1590/s1679-45082013000400015. Einstein (Sao Paulo). 2013. PMID: 24488390 Free PMC article.
-
Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Rheumatol Int. 2015 Jul;35(7):1193-210. doi: 10.1007/s00296-015-3222-4. Epub 2015 Feb 1. Rheumatol Int. 2015. PMID: 25638015
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical